Industry
Biotechnology
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT543 that is in Phase 1 clinical trials in select solid tumors and myeloid malignancies; and PRT811, which is in Phase 1 clinical trials in solid tumors, including glioblastoma multiforme. The company is also developing PRT1419, a potent and selective inhibitor of the anti-apoptotic protein; PRT2527, a potent inhibitor of CDK9 that exhibits high kinome selectivity; PRT-SCA2, which is in preclinical stage for multiple genomically selected cancers; PRT3645, a brain penetrant molecule that potently and selectively targets CDK4/6; and PRT-K4 that is in preclinical stage for solid tumors. The company was incorporated in 2016 and is headquartered in Wilmington, Delaware.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
December 19, 2023 | 2:33 pm
Portfolio Pulse from Benzinga Newsdesk
November 07, 2023 | 6:20 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2023 | 9:50 pm
Portfolio Pulse from Benzinga Newsdesk
November 01, 2023 | 9:18 pm
Portfolio Pulse from Lisa Levin
October 19, 2023 | 12:03 pm
Portfolio Pulse from Benzinga Insights
October 19, 2023 | 12:00 pm
Portfolio Pulse from Benzinga Newsdesk
October 19, 2023 | 11:06 am
Portfolio Pulse from Benzinga Insights
October 10, 2023 | 5:09 pm
Portfolio Pulse from Benzinga Insights
September 15, 2023 | 3:52 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.